Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Zelda Therapeutics — Investor Presentation (September 2018)
27 slides from Zelira Therapeutics's investor presentation, Sep 25, 2018
Slide 1: Updated Investor Presentation September 2018
For personal use only UPDATED INVESTOR PRESENTATION SEPTEMBER 2018 ASX: ZLD OTCQB: ZLDAF WWW.ZELDATHERAPEUTICS.COM
Slide 2: Disclaimer & Important Notice
DISCLAIMER & IMPORTANT NOTICE For personal use only Disclaimer This presentation has been prepared by Zelda Therapeutics Ltd ACN 103 782 378 (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Comp
Slide 3: Corporate Vision
CORPORATE VISION For personal use only OUR VISION • Become a global leader in clinical validation of medicinal cannabis and rapid delivery of transformative medicines to patients. OUR STRATEGY • Singular focus on clinical trials that address unmet needs of patients and clinicians for clinically vali
Slide 4: Overview
OVERVIEW ZELDA THERAPEUTICS OFFERS INVESTORS EXPOSURE TO A WORLD-CLASS TEAM AT VERY ATTRACTIVE VALUATIONS For personal use only AND WITH SIGNIFICANT VALUATION DRIVERS OVER THE NEXT 12-18 MONTHS GLOBALLY EXPANDING INDUSTRY Medical cannabis is one of the world’s fastest growing industries with increas
Slide 5: Corporate Snapshot
CORPORATE SNAPSHOT HISTORY SHARE PRICE (as at 20 Sep 2018) For personal use only • Focussed on clinical validation and rapid delivery of medicinal cannabis therapies to market. • Founded in August 2015 and listed on ASX November 2016. • Access to US patient data informs clinical development. • Exper
Slide 6: Board & Management
BOARD & MANAGEMENT For personal use only Dr Richard Hopkins Harry Karelis Dr Stewart Washer Mara Gordon Jason Peterson Managing Director Founder & Executive Founder & Director Founder & Director Founder & Director Chairman Richard is an experienced Harry is a co-founder of Stewart has 25 years of Ma
Slide 7: Medical Advisory Team
MEDICAL ADVISORY TEAM For personal use only Professor Manuel Guzman Dr Cristina Sanchez Dr Noah Federman Dr David Casarett Dr Dustin Sulak Professor of Biochemistry Assistant Professor at Paediatric clinical and Professor of Medicine and Dustin Sulak is an and Molecular Biology at Complutense Univer
Slide 8: Milestones Achieved
MILESTONES ACHIEVED For personal use only Insomnia Clinical Trial Patient Recruitment Completed Manufacturing & Distribution Agreement with Knop Research into Cannabinoids and Strategic partnership with Diabetes related Studies Breast Cancer | Expanded German group HAPA Research on Cancer Stem-like
Slide 9: Strategic Partnerships
STRATEGIC PARTNERSHIPS For personal use only Manufacturing and distribution partner for Zelda Australian animal health company developing products in Germany medicinal cannabis products for animal markets. Zelda has options over ~7% of CannPal. Pancreatic cancer and cognitive decline Autism Clinical
Slide 10: How Are We Different?
For personal use only HOW ARE WE DIFFERENT? 10
Slide 11: Strategic Focus on Rapidly Growing Medicinal Cannabis Sector
STRATEGIC FOCUS ON RAPIDLY GROWING MEDICINAL CANNABIS SECTOR For personal use only Prescription • Global Medicinal Cannabis Market worth $12 billion in 20181 . Medicinal CBD Wellness Pharmaceuticals • Forecast to grow to $40-55 billion 20281,2 (18% CAGR). Cannabis • ~ 1% of populations in US and Can
Slide 12: Strategic Focus on Whole-Plant Extracts and Entourage Effect
STRATEGIC FOCUS ON WHOLE-PLANT EXTRACTS AND “ENTOURAGE EFFECT” For personal use only THC CBD Tetrahydrocannabinol Cannabidiol Nausea1 Epilepsy1 Natural Plant Extracts Anorexia1 Pain Spasticity1 Inflammation Pain Stress Anxiety Cancer THCa CBGa CBDV CBL CBC CBN >113 other cannabinoids >300 terpenes T
Slide 13: Focus on Emerging Large Patient Markets
FOCUS ON EMERGING LARGE PATIENT MARKETS For personal use only BREAST CANCER INSOMNIA Most common cancer in women with > 2 million new cases Insomnia affects approx. 35% of adults diagnosed each year PANCREATIC CANCER 12th most common cancer globally with very poor prognosis AUTISM (<4% 5yr survival
Slide 14: Active Intellectual Property Strategy
ACTIVE INTELLECTUAL PROPERTY STRATEGY For personal use only • Working with Australia’s leading patent attorney firm. Patent Priority Date Filing • Seven patent families filed: Cancer August 2016 WO2018/023166 - Cancer - Skin Disease (topical) Skin Disease August 2016 WO2018/023164 - Sleep Disorders
Slide 15: Preclinical: Strategic Focus on Cancer to Generate Novel IP
PRECLINICAL: STRATEGIC FOCUS ON CANCER TO GENERATE NOVEL IP For personal use only Commercialisation CLINICAL TRIALS BREAST Cancer Preclinical Portfolio of PANCREATIC DIAGNOSTICS Data-packs novel IP assets BRAIN NOVEL THERAPIES 15
Slide 16: Commercialisation Model
COMMERCIALISATION MODEL For personal use only Design Create Deliver Commercialisation Conduct studies with research institutions License or partner with leading Design key pre-clinical and specialist clinical research organisations pharma/biotech Commercialisation and clinical studies (CROs) or dist
Slide 17: Comparative Analysis
COMPARATIVE ANALYSIS For personal use only Company Market Focus Capitalisation1 Zelda Therapeutics AUD $54m Research: Insomnia, Cancers, Autism (ASX:ZLD) and Skin disorders GW Pharma - Revenue US$11m FY17 AusCann AUD$300m Grow & Manufacture: Chronic and - 45 Phase 2/3 clinical trials (ASX:AC8) Neuro
Slide 18: Upcoming Activity & Milestone Pipeline
For personal use only UPCOMING ACTIVITY & MILESTONE PIPELINE BREAST CANCER AUTISM Follow-on studies focused on in vivo testing in conjunction with Recruitment for observational chemotherapy. trial commenced. BRAIN CANCER PANCREATIC CANCER SLEEP DISORDER Clinical trials commenced in Preclinical studi
Slide 19: Strong Strategic Positioning
STRONG STRATEGIC POSITIONING For personal use only • Global early mover in the medical space. • Ongoing establishment of research collaborations with leading global institutions. • Global strategic partnerships in place covering supply, manufacture and distribution. • Dynamic intellectual property s
Slide 20: Contact Us
CONTACT US For personal use only Dr Richard Hopkins Managing Director and CEO AUSTRALIA Level 26 140 St Georges Tce Perth WA 6000 +61 413 056 628 rhopkins@zeldatherapeutics.com @ZELDATHERAPEUTICS WWW.ZELDATHERAPEUTICS.COM 20
Slide 21: Appendix
For personal use only 21 APPENDIX
Slide 22: Clinical: Autism Positive Observational Study
CLINICAL For personal use only AUTISM | POSITIVE OBSERVATIONAL STUDY • Observational study in Chile, demonstrated successful results for treating core symptoms of autism. • Results were presented at the prestigious 23rd World Congress of Neurology in Kyoto, Japan. • Results demonstrate cannabis extr
Slide 23: Clinical: Insomnia
CLINICAL For personal use only INSOMNIA • Insomnia affects approximately 35% of adults. Current Insomnia treatment • Benzodiazepines are tranquilisers usually prescribed for anxiety and insomnia. • Overdoses from these cause almost 3 times more deaths than heroin & methamphetamine combined. Zelda’s
Slide 24: Pre-clinical: Breast Cancer
PRE-CLINICAL For personal use only BREAST CANCER • Zelda’s plant-derived THC formulations shown to have anti-cancer effect against a range of breast cancers, including triple negative, which is the most lethal form. • Zelda’s THC-rich formulation have greater anti-cancer effect than synthetic THC ac
Slide 25: Pre-clinical: Pancreatic Cancer
PRE-CLINICAL For personal use only PANCREATIC CANCER • 12th most common cancer. Very poor prognosis with 1 year survival rates <20%. Urgent need for new therapies and biomarkers to facilitate early diagnosis. • Collaborator published data showing novel combination of CBD and gemcitabine improves sur
Slide 26: Pre-clinical: Paediatric Brain Cancer
PRE-CLINICAL For personal use only PAEDIATRIC BRAIN CANCER • Medulloblastoma is the most common malignant brain tumour in children1. Clinical evidence supports the use of cannabinoids to treat glioblastoma. • Collaboration with world leading Brain Cancer team from Telethon Kids Institute with expert
Slide 27: Pre-clinical: Diabetes Related Cognitive Decline
PRE-CLINICAL For personal use only DIABETES RELATED COGNITIVE DECLINE • Diabetes is a chronic disease that can lead to a number of complications including the damage to blood vessels in the brain, associated with cognitive decline that can lead to dementia and other related conditions. • Zelda’s res
Zelda Therapeutics — Investor Presentation (September 2018) on 6ix